Home » Stocks » CABA

Cabaletta Bio, Inc. (CABA)

Stock Price: $11.57 USD -0.65 (-5.32%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 278.14M
Revenue (ttm) n/a
Net Income (ttm) -25.69M
Shares Out 24.04M
EPS (ttm) -10.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $11.57
Previous Close $12.22
Change ($) -0.65
Change (%) -5.32%
Day's Open 12.11
Day's Range 11.20 - 12.49
Day's Volume 43,383
52-Week Range 5.51 - 19.63

More Stats

Market Cap 278.14M
Enterprise Value 158.34M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 24.04M
Float 17.02M
EPS (basic) 2.42
EPS (diluted) -10.97
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.09M
Short Ratio 13.00
Short % of Float 6.40%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.24
Revenue n/a
Operating Income -26.98M
Net Income -25.69M
Free Cash Flow n/a
Net Cash 119.80M
Net Cash / Share 4.98
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -16.39%
ROE -25.61%
ROIC -637.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(87.29% upside)
Current: $11.57
Target: 21.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-18.68-6.19
Net Income-16.94-12.20
Shares Outstanding24.031.78
Earnings Per Share-4.07-6.87
Operating Cash Flow-16.05-4.66
Capital Expenditures-0.69-
Free Cash Flow-16.74-4.66
Cash & Equivalents13633.02
Net Cash / Debt13633.02
Book Value138-10.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cabaletta Bio, Inc.
Country United States
Employees 31
CEO Steven Nichtberger

Stock Information

Ticker Symbol CABA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CABA
IPO Date October 25, 2019


Cabaletta Bio, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.